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Enjeux et contexte: L'hyponatrémie est un trouble électrolytique fréquent et associé à un 
pronostic défavorable dans de nombreuses affections cardiovasculaires (1-5), pour lesquelles il 
est un marqueur de l'activation neurohumorale (6). Sa valeur pronostique chez les patients se 
présentant avec une embolie pulmonaire était jusque là inconnue ; elle fait l'objet de la présente 
étude. 
Objectifs: Examiner chez les patients hospitalisés pour une embolie pulmonaire, les 
associations entre hyponatrémie et mortalité ainsi qu'avec le taux de réhospitalisation. 
Méthodes: Nous avons étudié les données de 13'728 patients avec un diagnostic principal 
d'embolie pulmonaire provenant de 185 hôpitaux en Pennsylvanie Uanvier 2000 à novembre 
2002.) Nous avons utilisé un modèle de régression logistique afin d'établir l'association 
indépendante entre le niveau de sodium lors de la présentation aux urgences et la mortalité 
ainsi que le taux de réhospitalisation durant 30 jours. Nous avons ajusté pour les 
caractéristiques du patient (race, assurance, sévérité de la maladie, usage de la thrombolyse) et 
de l'hôpital (région, taille, avec ou sans médecins en formation.) 
Résultats principaux: Une hyponatrémie (sodium ::; 135 mmol/I) était présente chez 2907 
patients (21.1%). Les patients avec un sodium >135, 130-135, et <130 mmol/I avaient une 
mortalité cumulée à 30 jours de 8.0%, 13.6%, et 28.5% (P <0.001 ), et un taux de réadmission 
de 11.8%, 15.6%, et 19.3% (P <0.001 ), respectivement. Comparés aux patients avec un sodium 
>135 mmol/I, les odd ratios ajustés concernant la mortalité étaient significativement plus 
important pour les patients avec un sodium compris entre 130 et 135 mmol/I (OR 1.53, 95% Cl: 
1.33-1.76) ou <130 mmol/I (OR 3.26, 95% Cl: 2.48-4.29). Les odd ratios ajustés concernant la 
réhospitalisation étaient également augmentés pour les patients présentant un sodium entre 130 
et 135 mmol/I (OR 1.28, 95% Cl: 1.12-1.46) ou <130 mmol/I (OR 1.44, 95% Cl: 1.02-2.02). 
Conclusions et perspectives: L'hyponatrémie est fréquente chez les patients se présentant 
avec une embolie pulmonaire, de plus elle est un prédicateur indépendant de la mortalité à court 
terme, ainsi que du taux de réhospitalisation. La natrémie est une information généralement 
disponible lors de l'établissement d'un pronostic. Bien que cette association soit compatible 
avec une activation neurohumorale, nous ne pouvons pas attester des mécanismes impliqués, 
du fait que notre étude ne donne pas d'informations sur d'autres étapes de la physiologie de 
cette association. 
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At a Glance Commentary: 
Scientific knowledge on the subject: Although associated with adverse outcomes in 
left ventricular heart failure, pneumonia, and pulmonary hypertension, the prognostic 
value of hyponatremia, a marker of neurohormonal activation, in patients with acute 
pulmonary embolism is unknown. 
What this study adds to the field: ln patients with acute pulmonary embolism, 
hyponatremia at presentation is common and is associated with a higher risk of 30-day 
mortality and readmission. Hyponatremia may serve as an easy-to-use marker to 
identify patients with pulmonary embolism who are at high-risk of adverse outcomes. 
Future studies should examine whether hyponatremia reflects neurohormonal activation 
and right ventricular dysfunction. 
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ABSTRACT 
Rationale: Although associated with adverse outcomes in other cardiopulmonary 
conditions, the prognostic value of hyponatremia, a marker of neurohormonal activation, 
in patients with acute pulmonary embolism is unknown. 
Objectives: To examine the associations between hyponatremia and mortality and 
hospital readmission rates for patients hospitalized with pulmonary embolism. 
Methods: We evaluated 13, 728 patient discharges with a primary diagnosis of 
pulmonary embolism from 185 hospitals in Pennsylvania (01/2000-11/2002). We used 
random-intercept logistic regression to assess the independent association between 
serum sodium levels at the time of presentation and mortality and hospital readmission 
within 30 days, adjusting for patient (race, insurance, severity of illness, use of 
thrombolytic therapy) and hospital factors (region, size, teaching status). 
Measurements and Main Results: Hyponatremia (sodium ::; 135 mmol/1) was present 
in 2907 patients (21.1 %). Patients with a sodium level >135, 130-135, and <130 mmol/I 
had a cumulative 30-day mortality of 8.0%, 13.6%, and 28.5% (P <0.001 ), and a 
readmission rate of 11.8%, 15.6%, and 19.3% (P <0.001 ), respectively. Compared to 
patients with a sodium >135 mmol/I, the adjusted odds of dying were significantly 
greater for patients with a sodium 130-135 mmol/I (OR 1.53, 95% Cl: 1.33-1.76) and a 
sodium <130 mmol/I (OR 3.26, 95% Cl: 2.48-4.29). The adjusted odds of readmission 
were also increased for patients with a sodium 130-135 mmol/I (OR 1.28, 95% Cl: 1.12-
1.46) and a sodium <130 mmol/I (OR 1.44, 95% Cl: 1.02-2.02). 
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Conclusions: Hyponatremia is common in patients presenting with pulmonary 
embolism and is an independent predictor of short-term mortality and hospital 
readmission. 
Word Count for the Abstract: 250 
Key Words: hyponatremia, prognosis, pulmonary embolism 
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INTRODUCTION 
Hyponatremia is a common electrolyte abnormality among hospitalized patients 
and is associated with poor outcomes in patients with acute and chronic 
cardiopulmonary diseases, such as left ventricular heart failure, acute myocardial 
infarction, and pneumonia (1-5). ln patients with left ventricular heart failure, 
hyponatremia is strongly correlated with plasma neurohormone concentrations (e.g., 
norepinephrine, renin, and angiotensin Il) all of which predict adverse outcomes (6). 
Neurohormone-mediated release of vasopression is responsible for the decrease in 
serum sodium in these patients (6). 
A more recent study demonstrated that hyponatremia was also associated with 
right ventricular dysfunction and poor survival in patients with pulmonary arterial 
hypertension (7). ln this study, the authors suggested that hyponatremia may result from 
neurohormonal activation and be a consequence of more advanced right ventricular 
dysfunction (7). 
Acute pulmonary embolism (PE) is a major health problem; in 2005, 140,000 
patients were discharged with a primary diagnosis of PE from U.S. hospitals (8), with an 
estimated average 30-day mortality of 9% (9). Early death following PE is strongly 
associated with right ventricular dysfunction ( 10). Based on a previously observed 
association between abnormal sodium levels and mortality in patients with PE (9), we 
hypothesized that a low serum sodium at baseline, a marker of neurohormonal 
activation, may indicate a worse prognosis in patients with this illness. 
Our goal was to examine the association between hyponatremia and 30-day 
mortality and hospital readmission using a large, statewide sample of patients with acute 
PE. If found, such association may be useful to risk-stratify patients with acute PE, given 
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that serum sodium is a low-cost, routinely available laboratory parameter. Sorne of the 
results of this study have been previously reported in the form of an abstract (11 ). 
METHODS 
Patient Identification and Eligibility 
We identified all patients with PE discharged from non-governmental acute 
care hospitals in Pennsylvania (01/01/2000-11/30/2002) using the Pennsylvania 
Health Care Cast Containment Council (PHC4) data base (9). We included in patients 
aged 2 18 years who were discharged with a primary International Classification of 
Diseases, 9th Clinical Modification diagnosis of PE or a secondary diagnosis for PE 
and one of the following primary diagnoses that represent complications or 
treatments of PE: respiratory failure, cardiogenic shock, cardiac arrest, secondary 
pulmonary hypertension, syncope, thrombolysis, and intubation/mechanical 
ventilation. A detailed methodological description is available in the online 
supplement. 
Patient and Hospital Characteristics 
Patient demographic characteristics and insurance status were abstracted 
from the PHC4 database (9). Baseline clinical and laboratory parameters were 
obtained by linking eligible patients to the MediQual Atlas database (9). We 
quantified severity of illness using the Pulmonary Embolism Severity Index (PESI), a 
validated prognostic mode! for patients with PE (9). The PESI comprises 11 routinely 
available clinical predictor variables. A total point score for a given patient is obtained by 
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summing the points for each applicable predictor. Based on the total score, each patient 
is classified into one of five severity classes (1-V), with 30-day mortality ranging from 
1.1 % to 24.5%. We ascertained the hospital characteristics from the PHC4 database 
and from the Council of Teaching Hospitals of the Association of American Medical 
Colleges. 
Definition of Hyponatremia and Outcomes 
We defined hyponatremia as a baseline serum sodium level s; 135 mmol/I. While 
no commonly accepted eut-point exist for defining hyponatremia, most recent 
cardiopulmonary studies used a serum sodium level s; 134-136 mmol/I to define the 
threshold (2, 7, 12). 
Our primary study outcome was all-cause mortality within 30 days of 
presentation based on the National Death Index (13). To ascertain our secondary 
outcome, hospital readmission for any reason to any acute care hospital in Pennsylvania 
within 30 days, we used the PHC4 database. 
Statistical Analyses 
To compare baseline characteristics for patient discharges across three levels of 
serum sodium (< 130, 130 to 135, > 135 mmol/I), we performed chi-square tests for 
categorical variables and Kruskal-Wallis tests for continuous variables. We used survival 
analyses and the log-rank test to compare the cumulative 30-day mortality and hospital 
readmission rates by sodium level. We also stratified our comparisons of mortality by 
sodium level and the five PESI severity classes. 
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We used multivariable logistic regression to examine the independent association 
between sodium level and mortality, after adjusting for patient race, insurance, severity 
of illness using PESI severity class, thrombolytic therapy, and hospital region, size and 
teaching status. To account for patient clustering within hospital, we used random-
intercept logistic regression with the two levels defined by patient and hospital site. We 
used the same logistic model to examine the association between sodium level and 
readmission in patients discharged alive. We also examined whether the addition of 
serum sodium increases the prognostic performance of the PESI using net 
reclassification and integrated discrimination improvement (14 ). 
RESULTS 
Of the 17, 733 patient discharges that met our inclusion criteria, we excluded 323 
with only a secondary code indicative of PE (1.8%), 767 patient transfers from another 
hospital (4.3%), 265 subsequent transfers to another hospital (1.5%), 777 discharges 
without a match to key clinical findings (4.4%), 70 without a linkage to the National 
Death Index (0.4%), and 1803 (10.2%) with an undocumented serum sodium at the time 
of presentation. The study cohort comprised 13, 728 patient discharges with a diagnosis 
of PE from 185 Pennsylvania hospitals; 2907 (21.1 %) had hyponatremia (serum level ::; 
135 mmol/I). Of these, 2598 (18.9%) had a sodium level 130 to 135 mmol/1 and 309 
(2.2%) had a sodium level < 130 mmol/I. Compared to the 13, 728 enrolled patients, the 
1803 excluded because of an undocumented serum sodium were significantly younger 
(median age, 64 vs 67 years; P <0.001) and were less likely to have a history of heart 
failure (10.7% vs 16.5%; P <0.001) and chronic lung disease (14.7% vs 18.9%; P 
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<0.001 ). Compared to eligible patients with a serum sodium documented, these 1803 
excluded patients were also less likely to have a pulse~ 11 O/minute (11.1 % vs 18.5%; P 
<0.001 ), a systolic blood pressure < 1 OO mm Hg (7.8% vs 10.8%; P <0.001 ), a 
respiratory rate ~ 30/minute (8.3% vs 15.4%; P <0.001 ), a body temperature < 36°C 
(14.4% vs 16.9%; P =0.007), an altered mental status (5.9% vs 7.5%; P =0.02), and an 
arterial oxygen saturation< 90% (3.9% vs 8.5%; P <0.001) at presentation. 
Comparison of Baseline Patient Characteristics by Serum Sodium Level 
As shown in Table 1, patients admitted with lower serum sodium were aider, 
more likely to have comorbid diseases (cancer, chronic lung disease, heart failure) and 
more likely to have signs of clinical severity (tachycardia, hypotension, tachypnea, 
hypothermia, altered mental status, hypothermia, and hypoxemia). Consequently, there 
were a higher proportion of patients in PESI risk classes IV and V among patients with 
lower serum sodium. Patients with lower serum sodium were also significantly more 
likely to have hyperglycemia and elevated serum creatinine. 
Association of Serum Sodium Level and 30-Day Mortality 
Overall, 1308 of 13, 728 patients (9.5%) died at 30 days. As shown in Figure 1, 
patients with a serum sodium > 135, 130 to 135, < 130 mmol/I had a cumulative 30-day 
mortality of 8.0%, 13.6%, and 28.5% (P <0.001 ), respectively. Mortality in these three 
groups diverged day 1 after admission and the difference continued to increase over the 
30-day follow-up. Mortality was also significantly increased among patients with lower 
serum sodium stratified by each of the five PESI risk classes at presentation (Table 2). 
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After adjustment for patient race, insurance, severity of illness using PESI risk 
class, administration of thrombolytic therapy, hospital region, and hospital size and 
teaching status (Table 3), the odds of 30-day mortality remained significantly increased 
for patients with a sodium level 130 to 135 mmol/I ( odds ratio [OR] 1.53, 95% confidence 
interval [Cl]: 1.33-1.76) and a sodium level < 130 mmol/I (OR 3.26, 95% Cl: 2.48-4.29). 
When the PESI risk class was replaced in the model with the 11 variables comprising 
the PESI and laboratory parameters (serum glucose> 250 mg/dl, serum creatinine > 1.5 
mg/dl, and serum troponin ~ 0.1 ng/ml) or when the 5951 patients with a history of 
cancer, chronic lung disease, or heart failure were excluded from analysis, the results 
remained similar. 
Patient reclassifications for 30-day mortality are summarized in Table 4. For 38 of 
1308 patients (2.9%) who died within 30 days of admission, classification improved 
using serum sodium level in addition to the PESI. Conversely, 154 of 12,420 patients 
(1.2%) who were alive within 30 days of admission were reclassified up. The net 
reclassification improvement was estimated at 1. 7% (P <0.001 ), corresponding to a 
modest but statistically significant improvement. The integrated discrimination 
improvement was also statistically significant (0.009; P <0.001 ). 
Association of Serum Sodium Level and 30-Day Readmission 
The 30-day readmission rate was estimated in 12, 762 patients, after the 
exclusion of 840 patients who died in the hospital, 91 who were still hospitalized at 30 
days after admission, and 35 with unknown readmission status. Of these, 1596 (12.5%) 
were readmitted within 30 days. As shown in Figure 2, patients with a sodium level > 
135, 130 to 135, and < 130 mmol/I had a cumulative 30-day readmission rate of 11.8%, 
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15.6%, and 19.3% (P <0.001 ), respectively. After adjustment (Table 3), patients with a 
sodium level 130 to 135 mmol/I (OR 1.28, 95% Cl: 1.12-1.46) and a sodium level < 130 
mmol/I (OR 1.44, 95% Cl: 1.02-2.02) had significantly increased odds of 30-day 
readmission. When the PESI risk class was replaced in the model with the 11 variables 
comprising the PESI and laboratory parameters (serum glucose > 250 mg/dl, serum 
creatinine > 1.5 mg/dl, and serum troponin;::: 0.1 ng/ml) or when the 5951 patients with a 
history of cancer, chronic lung disease, or heart failure were excluded from analysis, the 
results were unchanged. 
DISCUSSION 
Our results demonstrate that a substantial proportion of patients with PE (21.1 % ) 
are hyponatremic at the time of presentation. After adjusting for potential patient- and 
hospital-related confounders and the administration of thrombolytic therapy, we found 
that patients with hyponatremia had a significantly higher 30-day mortality than patients 
without hyponatremia and that the mortality rate increased with the severity of 
hyponatremia. The higher mortality among patients with hyponatremia was observed 
across all PESI risk classes. Similarly, we also observed a significant association 
between hyponatremia and 30-day hospital readmission. To our knowledge, our study 
represents the first to demonstrate the prognostic importance of hyponatremia in 
patients with PE. 
Several explanations are possible for the association between hyponatremia and 
increased 30-day mortality in patients with PE. Hyponatremia is a well-known marker of 
neurohormonal activation in patients with left ventricular heart failure and reflects 
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nonosmotic release of vasopressin consequent to activation of the sympathetic and 
renin-angiotensin-aldosterone system axis (6, 15). Neurohormonal activation has also 
been demonstrated in patients with pulmonary arterial hypertension, and occurs in 
proportion to the degree of right ventricular dysfunction (16, 17). Therefore, 
hyponatremia may indicate neurohormonal activation in the context of PE-related 
pulmonary arterial hypertension and subsequent right heart dysfunction, a known factor 
of adverse prognosis in patients with PE (10). lndeed, a prior prospective study of 
patients with chronic pulmonary arterial hypertension demonstrated a strong association 
between hyponatremia and the presence of right ventricular dysfunction and short-term 
survival (7). Future prospective studies should examine whether hyponatremia reflects 
neurohormonal activation and right ventricular dysfunction in patients with acute PE. 
Another explanation for the observed association between hyponatremia and 
adverse outcomes may be the presence of unmeasured prognostic factors that are 
unrelated to right ventricular dysfunction. ln a recent study of middle-aged and elderly 
community subjects without a history of heart failure, hyponatremia was an independent 
predictor of death, regardless of concomitant diuretic use, renal and hepatic disease, 
and hyperglycemia (18). ln large retrospective and prospective cohort studies, 
hyponatremia also significantly increased short-term mortality in unselected inpatients 
(19-22). lndeed, the relationship between hyponatremia and adverse outcomes is 
incompletely understood because of its association with a multitude of underlying 
disease states, and its multiple causes with different pathophysiologic mechanisms (23). 
Our study also shows that after adjustment for patient and hospital characteristics 
and the administration of thrombolytic therapy, hyponatremia in the acute phase of PE is 
an independent predictor for future hospital admissions, reinforcing the prognostic 
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importance of a low serum sodium level. Our findings are consistent with the results 
from prior studies that found significantly higher hospital readmission rates in 
hyponatremic patients with acute myocardial infarction and heart failure (2, 12, 24 ). 
Our findings have both clinical and research implications. Clinically, patients with 
PE who are hyponatremic at presentation, carry a higher risk of short-term mortality and 
hospital readmission and may therefore potentially benefit from more intensive 
surveillance in the hospital and after discharge. Further research is warranted to 
determine whether correction of hyponatremia (e.g., with vasopressin receptor 
antagonists or other treatments) is associated with improved outcomes for patients with 
PE. Evidence suggests that patients with left ventricular heart failure who have 
persistent hyponatremia have a significantly higher risk of short-term mortality or 
hospitalization for heart failure than patients in whom hyponatremia was corrected (24 ). 
Similarly, resolution of admission hyponatremia during hospitalization appears to 
attenuate the increased mortality risk conferred by hyponatremia among unselected 
inpatients (21 ). 
Our work has several potential limitations. First, patients in the study sample were 
identified by use of ICD-9-CM codes for PE rather than standardized radiographie 
criteria, and patient eligibility may therefore be subject to study selection biases due to 
hospital coding procedures. ln prior studies, up to 96% of patients with specific codes for 
PE had objectively documented disease on the basis of chart review criteria (25-27). 
Second, our sample excluded 10.2% of younger, healthier, and less severely ill patients 
in whom serum sodium was not measured at the time of admission. However, because 
hyponatremia adversely affects outcomes across the full spectrum of severity of illness 
(PESI risk classes 1-V), the exclusion of these lower risk patients is unlikely to change 
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our study results. Third, because measures of right ventricular function and 
neurohormonal activation were not available in our database, we could not examine 
whether these factors are linked to the pathophysiology of hyponatremia. Moreover, we 
had no information about diuretic use and hypervolemic hyponatremic states such as 
cirrhosis or nephrotic syndrome. Thus, we could not explore whether these conditions 
are associated with the higher observed mortality among patients with hyponatremia. 
Fourth, because we had no information on sodium levels after hospital discharge, the 
prognostic implications of transient versus persistent hyponatremia could not be 
analyzed. Finally, we can only detect associations, not causality from these data. Thus, 
we cannot determine whether hyponatremia has a specific effect on the pathophysiology 
of PE or if it is simply a marker of adverse outcome. 
ln conclusion, in this large sample of patients hospitalized with acute PE, 
hyponatremia at presentation was common and was associated with a higher risk of 30-
day mortality and readmission. Hyponatremia may serve as an easy-to-use marker to 
identify patients with PE who are at high-risk of adverse medical outcomes. Future 
studies should examine whether hyponatremia reflects neurohormonal activation and 
right ventricular dysfunction in patients with acute PE and whether correction of this 
electrolyte abnormality is associated with improved patient outcomes. 
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Figure Legend 1 
Cumulative Mortality by Level of Serum Sodium 
Kaplan-Meier estimates of 30-day mortality for patients with pulmonary embolism by 
baseline level of serum sodium. The cumulative mortality was 8.0%, 13.6%, and 28.5% 
for patients with a sodium level > 135, 130 to 135, and < 130 mmol/I (P <0.001 ), 
respectively. 
21 
Figure Legend 2 
Cumulative Readmission Rate by Level of Serum Sodium 
Kaplan-Meier estimates of 30-day readmission rate for patients with pulmonary 
embolism by baseline level of serum sodium. The cumulative readmission rate was 
11.8%, 15.6%, and 19.3% for patients with a sodium level > 135, 130 to 135, and < 130 
mmol/I (P <0.001 ), respectively. 
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Table 1. Baseline Patient Characteristics by Level of Serum Sodium 
Serum Sodium Level (mmol/I) 
Characteristics Ali patients <130 130 to 135 >135 P-Value 
{N=13,728} {N=309} {N=2598} {N=10,821} 
Number (%) or Median (IQR) 
Demographics 
Age, years 67 (52-77) 71 (59-79) 68 (55-78) 67 (52-77) <0.001 
Male gender 5525 (40.2) 122 (39.5) 1099 (42.3) 4304 (39.8) 0.06 
Race 0.38 
White 11166 (81.3) 249 (80.6) 2149 (82.7) 8768 (81.0) 
Black 1459 (10.6) 34 (11.0) 252 (9.7) 1173(10.8) 
Other/unknown 1103 (8.0) 26 (8.4) 197 (7.6) 880 (8.1) 
lnsurance status <0.001 
None/unspecified 197 (1.4) 1 (0.3) 37(1.4) 159 (1.5) 
Government 7685 (56.0) 205 (66.3) 1513 (58.2) 5967 (55.1) 
Medicaid 1013 (7.4) 25 (8.1) 204 (7.8) 784 (7.2) 
Priva te 4833 (35.2) 78 (25.2) 844 (32.5) 3911 (36.1) 
Comorbid diseases 
History of cancer 2669 (19.4) 105 (34.0) 685 (26.4) 1879 (17.4) <0.001 
Chronic lung disease 2602 (18.9) 68 (22.0) 540 (20.8) 1994 (18.4) 0.009 
Heart failure 2266 (16.5) 80 (25.9) 494 (19.0) 1692 (15.6) <0.001 
Continued 
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Table 1 Continued 
Serum Sodium Level (mmol/I) 
Characteristics Ali patients <130 130 to 135 >135 P-Value 
{N=13,728} {N=309) (N=2598} (N=10,821} 
Number (%)or Median (IQR) 
Physical examination findings 
Pulse?: 110 beats per minute 2542 (18.5) 87 (28.2) 596 (22.9) 1859 (17.2) <0.001 
Systolic blood pressure < 1 OO mm Hg 1484 (10.8) 65 (21.0) 417 (16.0) 1002 (9.3) <0.001 
Respiratory rate ?: 30 breaths/minute 2111 (15.4) 69 (22.3) 446 (17.2) 1596 (14.7) <0.001 
Altered mental status* 1024 (7.5) 39 (12.6) 218(8.4) 767 (7.1) <0.001 
Temperature < 36°C 2316(16.9) 64 (20.7) 403 (15.5) 1849 (17.1) 0.03 
Arterial oxygen saturation < 90%t 1165 (8.5) 30 (9.7) 250 (9.6) 885 (8.2) 0.04 
Laboratory parameters 
Glucose > 250 mg/dl 1000 (7.3) 54 (17.5) 335 (12.9) 611 (5.6) <0.001 
Creatinine > 1.5 mg/dl 1809 (13.2) 67 (21.7) 412(15.9) 1330 (12.3) <0.001 
Troponin ?: 0.1 ng/ml 4497 (32.8) 106 (34.3) 817 (31.4) 3574 (33.0) 0.26 
PESI risk class <0.001 
2531 (18.4) 12 (3.9) 334 (12.9) 2185 (20.2) 
Il 2894 (21.1) 45 (14.6) 463 (17.8) 2386 (22.0) 
Ill 3018 (22.0) 65 (21.0) 578 (22.2) 2375 (21.9) 
IV 2253 (16.4) 70 (22.6) 512 (19.7) 1671 (15.4) 
V 3032 (22.1) 117 (37.9) 711 (27.4) 2204 (20.4) 
Continued 
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Table 1 Continued 
Serum Sodium Level (mmol/I) 
Characteristics Ali patients <130 130 to 135 >135 P-Value 
(N=13,728) (N=309) (N=2598) (N=10,821) 
Number (%)or Median (IQR) 
Thrombolysis 329 (2.4) 6 (1.9) 75 (2.9) 248 (2.3) 0.19 
Types of hospitals attended 
Hospital region <0.001 
Pittsburgh and surrounding areas 3174 (23.1) 66 (21.4) 509 (19.6) 2599 (24.0) 
Northwest Pennsylvania 947 (6.9) 20 (6.5) 187 (7.2) 740 (6.8) 
Southern Laurel Highlands 713 (5.2) 11 (3.6) 124 (4.8) 578 (5.3) 
North central Pennsylvania 942 (6.9) 21 (6.8) 211 (8.1) 710 (6.6) 
South central Pennsylvania 2187 (15.9) 57(18.4) 451 (17.4) 1679 (15.5) 
Northeast Pennsylvania 841 (6.1) 23 (7.4) 179 (6.9) 639 (5.9) 
Eastern Pennsylvania 1366 (9.9) 19 (6.1) 288 (11.1) 1059 (9.8) 
Surrounding Philadelphia 2037 (14.8) 36 (11.6) 314 (12.1) 1687 (15.6) 
Philadelphia 1521 (11.1) 56 (18.1) 335 (12.9) 1130 (10.4) 
Average an nuai volume of PE, 
0.02 
quartiles 
< 10 747 (5.4) 8 (2.6) 147 (5.7) 592 (5.5) 
10 to 20 1569 (11.4) 30 (9.7) 257 (9.9) 1282 (11.8) 
21 to 42 3517 (25.6) 87 (28.2) 686 (26.4) 2744 (25.4) 
> 42 7895 (57.5) 184 (59.5) 1508 (58.0) 6203 (57.3) 
Continued 
25 
Table 1 Continued 
Serum Sodium Level (mmol/I) 
Characteristics Ali patients <130 130 to 135 >135 P-Value 
{N=13,728} {N=309} (N=2598} (N=10,821} 
Number (%) or Median (IQR) 
Hospital size and teaching status <0.001 
Large nonteaching (~ 350 beds) 2748 (20.0) 73 (23.6) 615 (23.7) 2060 (19.0) 
Small nonteaching (< 350 beds) 7542 (54.9) 149 (48.2) 1337 (51.4) 6056 (56.0) 
Teaching 3438 (25.1) 87 (28.2) 646 (24.9) 2705 (25.0) 
Abbreviations: IQR = interquartile range; PE = pulmonary embolism; PESI = Pulmonary Embolism Severity Index. 
*Defined as disorientation, lethargy, stupor, or coma. 
tWith or without supplemental oxygen. 
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Table 2. Association of Mortality and Level of Serum Sodium Stratified by 
Severity of lllness 
Serum Sodium Level (mmol/I) 
<130 130to135 >135 P-Value 
30-Day Mortality, n/N (%) 
PESI risk class 
0/12 (0.0) 10/334 (3.0) 22/2185 (1.0) 0.02 
Il 7/45 (15.6) 28/463 (6.0) 62/2386 (2.6) <0.001 
Ill 16/65 (24.6) 52/578 (9.0) 134/2375 (5.6) <0.001 
IV 15/70 (21.4) 73/512 (14.3) 156/1671 (9.3) <0.001 
V 50/117 (42.7) 190/711 (26.7) 493/2204 (22.4) <0.001 
Abbreviation: PESI = Pulmonary Embolism Severity Index. 
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Table 3. Association Between Level of Serum Sodium and Outcomes 
Outcomes Adjusted 95% Confidence P-Value 
Odds Ratio* lnterval 
30-day all-cause mortality <0.001 
Serum sodium >135 mmol/I 1.00 
Serum sodium 130 to 135 mmol/I 1.53 1.33-1.76 
Serum sodium <130 mmol/I 3.26 2.48-4.29 
30-day hospital readmission ratet <0.001 
Serum sodium >135 mmol/I 1.00 
Serum sodium 130 to 135 mmol/1 1.28 1.12-1.46 
Serum sodium <130 mmol/I 1.44 1.02-2.02 
*The models were adjusted for patient race, insurance type, severity of illness using the Pulmonary Embolism 
Severity Index (including age, gender, history of cancer, chronic lung disease, or heart failure, systolic arterial blood 
pressure < 1 OO mm Hg, pulse ?' 11 O/min., respiratory rate ?' 30 breaths/min., body temperature < 36°C, arterial 
oxygen saturation < 90%, altered mental status), administration of thrombolysis, hospital region within Pennsylvania, 
and hospital size and teaching status. Adjusted odds ratios were estimated using random-intercept logistic regression 
with the two levels defined by patient and hospital site. 
tThirty-day readmission was estimated after the additional exclusion of 840 patients who died in the hospital, 91 who 
were still hospitalized 30 days after admission, and 35 with unknown readmission status, leaving a sample of 12,762 
patients. 
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Table 4. Reclassification of Patients Who Died and Who Were Alive by 30 Days Based on the PESI With and Without 
Serum Sodium Level 
PESI Without Serum PESI With Serum Sodium Level (<130, 130 to 135, >135 mmol/I) 
Sodium Level 
Frequency <2.3% 2.3-5.0% 5.1-8.8% 8.8-17.5% >17.5% Total 
Patients who died by 30 days 
<2.3% 32 0 0 0 0 32 
2.3-5.0% 0 90 0 7 0 97 
5.1-8.8% 0 0 186 16 0 202 
8.8-17.5% 0 0 0 229 15 244 
>17.5% 0 0 0 0 733 733 
Total 32 90 186 252 748 1308 
Patients who were alive by 30 days 
<2.3% 2487 12 0 0 0 2499 
2.3-5.0% 0 2759 0 38 0 2797 
5.1-8.8% 0 0 2767 49 0 2816 
8.8-17.5% 0 0 0 1954 55 2009 
>17.5% 0 0 0 0 2299 2299 
Total 2487 2771 2767 2041 2354 12420 
Abbreviations: PESI = Pulmonary Embolism Severity Index 
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